First RNA-Based Blood Test Available for IBS, IBD Diagnoses, IQuity Announces

First RNA-Based Blood Test Available for IBS, IBD Diagnoses, IQuity Announces
IQuity, a leading life science technology company in the field of RNA-based diagnosis, announced the release of IsolateIBS-IBD, a pioneering blood test that helps clinicians identify with great accuracy irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), allowing patients to receive treatment much faster. The test analyzes a person’s RNA (the intermediate molecule between DNA and protein) retrieved from a small blood sample and identifies with 90% accuracy if someone carries a genetic signature for either IBD or IBS. Because both of these diseases share many symptoms but require unique treatments, a correct diagnosis can be challenging, with patients undergoing a battery of tests including X-rays, stool analyses, and invasive endoscopies. However, even with these tests, it can still take physicians several months to reach a diagnosis. As such, IsolateIBS-IBD represents a key breakthrough for the clinical management of both diseases. Among IBD patients, the test also can distinguish between Crohn's disease and ulcerative colitis. "The process of diagnosing IBS and IBD can be time-consuming and physically and emotionally draining for patients," Chase Spurlock, chief executive officer of IQuity, said in a press release. "With IsolateIBS-IBD, we're providing a potent new tool to aid physicians as they work with patients to achieve an accurate, early diagnosis. We want to help eliminate uncertainty and give physicians and patients information
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *